Expert Interviews

REVIEW UroToday

Expert Interviews

Search

$A New Era In Systemic Therapies, Pembrolizumab for High Risk Non-Muscle Invasive BCG-Refractory Patients - Arjun Balar$ A New Era In Systemic Therapies, Pembrolizumab for High Risk Non-Muscle Invasive BCG-Refractory Patients - Arjun Balar Details Arjun Balar and Alicia Morgans discuss the new era in systemic therapies in non-muscle invasive bladder cancer (NMIBC) focusing on the systemic checkpoint inhibitor, pembrolizumab that resulted in the US FDA approval of pembrolizumab for treatment in early bladder cancer. Historically being in the domain of urologic oncologists, Drs. Morgans and Balar discuss the importance of the medical oncologi...
Monoallelic vs Biallelic BRCA2 Alterations, PARP Inhibitors in Prostate Cancer - Colin Pritchard Details Colin Pritchard joins Charles Ryan at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) where they discuss PARP inhibitor data that came out of the 2019 ESMO meeting including the PROfound study data, rucaparib in TRITON2, and niraparib in the GALAHAD study and focusing on monoallelic versus biallelic BRCA2 alterations. Biographies: Colin C Pritchard, M.D., Ph.D. is the Dire...
Advances in PSMA-directed Radionuclide Therapy - Howard Soule Details Howard Soule discusses highlights and his takeaways from the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. Dr. Soule highlights the importance of coming to these conferences to understand where the gaps are in the treatment landscape and the benefit of these global conferences for clinicians from resource-limited countries. They continue on to discuss imaging, PSMA, and the VISION tr...
Understanding Differences in Outcomes of Men with Prostate Cancer Based on Race and Ethnicity - Christopher Logothetis Details Christopher Logothetis and Charles Ryan review key takeaways from Christopher Logothetis's Advanced Prostate Cancer Consensus Conference (APCCC 2019) presentation on Ethnicity and Prognosis of Prostate Cancer and the importance in understanding the differences in outcomes of individuals with the disease based on race and ethnicity. In his work Dr. Logothetis prepared for APCCC 2019, he presses the...